Research suggests that working with a single contract partner can reduce development time and improve economics.
Competitive pressures have led to explosive growth in demand for research and development (R&D) outsourcing, especially as smaller biopharma and pharmaceutical companies play a more prominent role in drug development. Pharmaceutical manufacturers, especially small- to mid-sized companies, are discovering that partnering more closely with one diversified contract company can reduce development time and cost.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
BioPharm International
eBook: Outsourcing Resources 2018
March 2018
Pages: 4–6
When referring to this article, please cite it as A. Shanley, “Outsourcing: Does Focus Pay Off?," BioPharm International Outsourcing Resources eBook (March 2018).
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.